&#xa0;
defaultWritten evidence submitted by Taintedblood.info (BTO0018)default&#xa0;
defaultExecutive Summary
default&#xa0;
defaultIntroduction
defaultMain Submission
defaultTable 3. Summary of health status of individuals at increased risk of CJD/defaultvCJDdefault (as at 30 June 2012)default'At risk' GroupdefaultIdentified as 'at risk'defaultEver notified as being 'at risk'defaultAlive and NotifieddefaultCJD/defaultvCJDdefault casesdefaultAsymptomatic defaultvCJDdefaultinfections defaultddefaultRecipients of blood from defaultvCJDdefault Casesdefault67
default27
default18
default3
default1
defaultBlood donors to defaultvCJDdefault casesdefault112
default107
default104
default-
default-
defaultOther recipients from blood donors to defaultvCJDdefault casesdefault34
default32
default22
default-
default-
defaultPlasma product recipients (all except one have non-bleeding disordersdefault11
default10
default4
default-
default-
defaultSurgical contacts of all CJD Casesdefault154
default129
default119
default-
default-
defaultHighly transfused patients default(recipients of blood from ≥80) defaultdonors identified at pre-surgical assessment)default&#xa0;
default10
default&#xa0;
default9
default&#xa0;
default8
default&#xa0;
default-
default&#xa0;
default-
defaultTotal for at risk groups where the HPA holds datadefault388default310default273default3default1defaultPatients with bleeding disorders who received UK sourced plasma products defaultadefault&#xa0;
default3,872default&#xa0;defaultn/adefault&#xa0;defaultn/adefault&#xa0;default-
default&#xa0;default1defaultRecipients of human derived growth hormone defaultbdefault1,883
default1,883
default1,513
default71
default-
defaultTotal for all ‘at risk’ groups defaultcdefault6,143default&gt;2,193default&gt;1,786default74default2default&#xa0;defaulta.default 
defaultData provided by the UK Haemophilia Centre Doctors' Organisation (UKHCDO). These are minimum figures. Central reporting for bleeding disorder patients is incomplete, and seven patients have opted out of the central UKHCDO database. Individual haemophilia centres were asked to send out standardised letters of notification to all their ‘at risk’ patients, but the exact number of patients who received these letters and are therefore aware of their risk is not known.
defaultb.default Data provided by the Institute for Child Health. A small number of ‘at risk' growth hormone recipients are not included in the Institute of Child Health study so the true number ‘at risk’ will be greater. The exact number of growth hormone recipients in the ICH study currently aware of their risk is not known, as given their age at the original notification many were informed indirectly, by their parents.
defaultc.default 
defaultThese are minimum figures given the comments made above.
default defaultd.default An asymptomatic infection is when an individual does not exhibit any of the signs and symptoms of CJD in life but abnormal 
defaultprion
default protein indicative of CJD infection has been found in tissue obtained from them. In these cases the abnormal 
defaultprion
default protein was identified during post mortem after the individuals had died of other causes.  
default&#xa0;
defaultRecommendations
defaultA clear communication policy should be employed to relay updates, precautionary action, etc., to product-users.
defaultA review of safety measures to account for emerging risks and ensure efficacy of manufacturing and viral inactivation processes.
defaultIndividuals should be given the opportunity to opt in or out of receiving notifications about screening tests or potential infection. Patients who opt in should be regularly updated on the evolution of knowledge and diagnostic tests.
defaultClear processes, responsibility and consent should exist in the collection of patient data.
defaultAs soon as is practicable, new technologies should be employed to further improve donor screening, therapeutic products, etc.
defaultJanuary 2014
default&#xa0;default&#xa0;
default